[go: up one dir, main page]

WO2005079748A3 - Pharmaceutical preparation for sustained release of a pharmaceutically active ingredient - Google Patents

Pharmaceutical preparation for sustained release of a pharmaceutically active ingredient Download PDF

Info

Publication number
WO2005079748A3
WO2005079748A3 PCT/EP2005/001154 EP2005001154W WO2005079748A3 WO 2005079748 A3 WO2005079748 A3 WO 2005079748A3 EP 2005001154 W EP2005001154 W EP 2005001154W WO 2005079748 A3 WO2005079748 A3 WO 2005079748A3
Authority
WO
WIPO (PCT)
Prior art keywords
active ingredient
pharmaceutically active
sustained release
pharmaceutical preparation
weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2005/001154
Other languages
French (fr)
Other versions
WO2005079748A2 (en
Inventor
Sanchez Francisco Jurado
Pablo Sedano Marta De
Campano Monica Argilaga
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lacer SA
Original Assignee
Lacer SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lacer SA filed Critical Lacer SA
Publication of WO2005079748A2 publication Critical patent/WO2005079748A2/en
Publication of WO2005079748A3 publication Critical patent/WO2005079748A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Pharmaceutical preparation for sustained release of a pharmaceutically active ingredient A pharmaceutical preparation for sustained release of a pharmaceutically active ingredient(s), which preparation comprises particles having an inner core (1) and a first coating (2) provided thereon, wherein said coating (2) contains a mixture of: (a) between 50% and 95% by weight of a copolymer of ethyl acrylate, methylmethacrylate and trimethylamminoethyl methacrylate chloride in a molar ratio of the three acrylates of 1 : 1.8-2.2 : 0.08­-0.12, preferably of 1:2:0.1, (b) between 2% and 30% by weight of a copolymer of ethylacrylate and methacrylic acid in a molar ratio of 1: 0.8-1.2, preferably of 1:1, and (c) between 1 % and 40% by weight of the pharmaceutically active ingredient.
PCT/EP2005/001154 2004-02-13 2005-02-04 Pharmaceutical preparation for sustained release of a pharmaceutically active ingredient Ceased WO2005079748A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200400338A ES2241478B1 (en) 2004-02-13 2004-02-13 PHARMACEUTICAL PREPARATION FOR THE SUSTAINED RELEASE OF A PHARMACEUTICALLY ACTIVE PRINCIPLE.
ESP200400338 2004-02-13

Publications (2)

Publication Number Publication Date
WO2005079748A2 WO2005079748A2 (en) 2005-09-01
WO2005079748A3 true WO2005079748A3 (en) 2006-06-08

Family

ID=34878429

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/001154 Ceased WO2005079748A2 (en) 2004-02-13 2005-02-04 Pharmaceutical preparation for sustained release of a pharmaceutically active ingredient

Country Status (2)

Country Link
ES (1) ES2241478B1 (en)
WO (1) WO2005079748A2 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1734931A2 (en) 2004-03-24 2006-12-27 Actavis Group Formulations of ramipril
US8007827B2 (en) * 2004-04-02 2011-08-30 Impax Laboratories, Inc. Pharmaceutical dosage forms having immediate release and/or controlled release properties
CA2613107A1 (en) * 2005-06-23 2007-01-04 Spherics, Inc. Delayed release or extended-delayed release dosage forms of pramipexole
EP1810668A1 (en) * 2006-01-23 2007-07-25 LEK Pharmaceuticals D.D. Coated formulations containing tolterodine tartrate
JP2007308479A (en) 2006-04-20 2007-11-29 Shin Etsu Chem Co Ltd Solid dispersion formulation
JP2007308480A (en) * 2006-04-20 2007-11-29 Shin Etsu Chem Co Ltd Solid preparation containing enteric solid dispersion
WO2008027557A2 (en) 2006-08-31 2008-03-06 Spherics, Inc. Topiramate compositions and methods of enhancing its bioavailability
US8298576B2 (en) * 2006-11-17 2012-10-30 Supernus Pharmaceuticals, Inc. Sustained-release formulations of topiramate
EP2175843B1 (en) * 2007-08-08 2014-10-08 Inventia Healthcare Private Limited Extended release compositions comprising tolterodine
EP2331052B1 (en) * 2008-09-03 2017-06-14 ELC Management LLC Compositions comprising solid particles encapsulated in a cross-linked silicone matrix, and methods of making the same
CN103316026B (en) 2012-03-23 2016-05-11 中国人民解放军军事医学科学院毒物药物研究所 Contain joint product of Phentermine and Topiramate and preparation method thereof
CN102579367B (en) * 2012-03-23 2014-03-12 中国人民解放军军事医学科学院毒物药物研究所 Topiramate sustained-release drug composition, method for preparing same and application of Topiramate sustained-release drug composition
US9457008B2 (en) 2012-03-23 2016-10-04 Institute Of Pharmacology And Toxicology Academy Of Military Medical Sciences P.L.A. China Joint product comprising synephrine and topiramate
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
SG11201600933QA (en) * 2013-08-06 2016-03-30 Tasly Pharmaceutical Group Co Application of andrographolide in the preparation of a pharmaceutical for treatment of inflammatory bowel disease, andrographolide enteric targeting micropellet, and method for preparation thereof
DE102018129419A1 (en) * 2018-11-22 2020-05-28 Johannes Gutenberg-Universität Mainz Acrylate copolymer for pharmaceutical applications

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0720473B1 (en) * 1993-09-23 1998-11-11 Dr. Falk Pharma Gmbh Budesonide pellets with a controlled release pattern and process for producing them
US6039979A (en) * 1999-01-13 2000-03-21 Laboratoires Prographarm Multiparticulate pharmaceutical form with programmed and pulsed release and process for its preparation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT93637A (en) * 1989-04-20 1990-11-20 Procter & Gamble METHOD FOR THE TREATMENT OF INTESTINAL / COLONIC FUNCTIONAL DISORDERS, ESPECIALLY THE INTESTINAL IRRITATION SYNDROME
US20030153607A1 (en) * 1998-11-12 2003-08-14 Smithkline Beecham P.L.C. Novel composition and use
DZ2937A1 (en) * 1998-11-12 2004-03-15 Smithkline Beecham Plc New compositions of insulin sensitizers.
CA2380333A1 (en) * 1999-08-26 2001-03-01 Christian Andina Pharmaceutical formulations

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0720473B1 (en) * 1993-09-23 1998-11-11 Dr. Falk Pharma Gmbh Budesonide pellets with a controlled release pattern and process for producing them
US6039979A (en) * 1999-01-13 2000-03-21 Laboratoires Prographarm Multiparticulate pharmaceutical form with programmed and pulsed release and process for its preparation

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
AKBUGA JULIDE: "Effect of microsphere size and formulaton factors on drug release from controlled-release furosemide microspheres", DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, vol. 17, no. 4, 1991, pages 593 - 607, XP008062720 *
PONGPAIBUL Y, PRICE JC, WHITWORTH CW: "Preparation and evaluation of controlled release indomethacin microspheres", DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, vol. 10, no. 10, 1984, pages 1597 - 1616, XP008062731 *
TSANKOV S, LAMBOV N; MINKOV E: "Regulation of tetracycline hydrochloride release from polyacrylate microspheres.", PHARMAZEUTISCHE INDUSTRIE, vol. 57, no. 12, 1995, pages 1044 - 1047, XP008062723 *

Also Published As

Publication number Publication date
ES2241478B1 (en) 2006-11-16
ES2241478A1 (en) 2005-10-16
WO2005079748A2 (en) 2005-09-01

Similar Documents

Publication Publication Date Title
WO2005079748A3 (en) Pharmaceutical preparation for sustained release of a pharmaceutically active ingredient
WO2005046649A3 (en) Multilayer pharmaceutical dosage form containing a substance that acts in a modulatory manner with regard to the release of active substances
WO2007006353A3 (en) Use of a partially neutralized, anionic (meth)acrylate copolymer as a coating for the production of a medicament releasing active substance at reduced ph values
CA2346062A1 (en) Coated medicament forms with controlled active substance release
EP2158905A3 (en) Composition for the Transdermal Delivery of Fentanyl
CA2370067A1 (en) Pharmaceutical dosage forms for controlled release producing at least a timed pulse
AU2003266351A1 (en) Multilayer dosage forms, which contain active substances and which comprise a neutral core, and an inner and outer coating consisting of methacrylate copolymers and methacrylate monomers
WO2005070462A3 (en) Compositions comprising (s)-amlodipine and an angiotensin receptor blocker and methods of their use
WO2004062577A3 (en) Two or more enteric materials to regulate drug release
IL151151A0 (en) Coating and binding agent for pharmaceutical formulations having improved storage stability
CA2494234A1 (en) Methods and dosage forms for controlled delivery of paliperidone
EP1287822A3 (en) Mesalazine controlled release oral pharmaceutical compositions
UA88056C2 (en) Once-a-day oxycodone formulations
CA2317106A1 (en) Method and composition of an oral preparation of itraconazole
WO2005041968A3 (en) Once-a-day, oral, controlled-release, oxycodone dosage forms
AU2002254036A1 (en) Taste masked pharmaceutical compositions
WO2004112756A8 (en) Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
WO2007000778A3 (en) Modified release pharmaceutical compositions on the basis of two polymers and processes thereof
WO2008084698A1 (en) Tacrolimus sustained release pharmaceutical composition
MX356579B (en) Gastric resistant pharmaceutical or nutraceutical composition with resistance against the influence of ethanol.
WO2007071581A3 (en) Pharmaceutical formulation for producing rapidly disintegrating tablets
WO2007011619A3 (en) Highly bioavailable oral delayed release dosage forms of o-desmethylvenlafaxine succinate
CA2470656A1 (en) Corticotropin releasing factor 2 receptor agonists
WO2006010394A3 (en) Medicament in a multilayer form
UA93530C2 (en) Composition with sustained release of an active ingredient, process for the preparation and use thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase